# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-23-011836
Filing Date
2023-04-11
Accepted
2023-04-11 16:05:09
Documents
5
Period of Report
2023-04-11

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | formdef14a.htm | DEF 14A | 362161
2 |  | proxy_001.jpg | GRAPHIC | 291289
3 |  | proxy_002.jpg | GRAPHIC | 219753
4 |  | proxy_003.jpg | GRAPHIC | 164753
5 |  | proxy_004.jpg | GRAPHIC | 148073
| Complete submission text file | 0001493152-23-011836.txt |  | 1498320

Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39717 | Film No.: 23813440
SIC: 2834 Pharmaceutical Preparations